[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1123031T1 - Ρυθμιστες της δραστικοτητας του συμπληρωματος - Google Patents

Ρυθμιστες της δραστικοτητας του συμπληρωματος

Info

Publication number
CY1123031T1
CY1123031T1 CY20201100292T CY201100292T CY1123031T1 CY 1123031 T1 CY1123031 T1 CY 1123031T1 CY 20201100292 T CY20201100292 T CY 20201100292T CY 201100292 T CY201100292 T CY 201100292T CY 1123031 T1 CY1123031 T1 CY 1123031T1
Authority
CY
Cyprus
Prior art keywords
regulators
supplement
effectiveness
modulators
polypeptide
Prior art date
Application number
CY20201100292T
Other languages
English (en)
Inventor
Steven James DEMARCO
Michelle Denise HOARTY
Grace Victoria PARKER
Alonso RICARDO
Sylvia TOBE
Douglas A. Treco
Original Assignee
Ra Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals, Inc. filed Critical Ra Pharmaceuticals, Inc.
Publication of CY1123031T1 publication Critical patent/CY1123031T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Medicinal Preparation (AREA)
  • Amplifiers (AREA)
  • Steroid Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε πολυπεπτιδικούς ρυθμιστές της δραστικότητας του συμπληρώματος, που περιλαμβάνουν κυκλικούς πολυπεπτιδικούς ρυθμιστές. Περιλαμβανόμενες είναι μέθοδοι χρήσης αυτών των ρυθμιστών ως θεραπευτικών μέσων.
CY20201100292T 2015-12-16 2020-03-27 Ρυθμιστες της δραστικοτητας του συμπληρωματος CY1123031T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562268360P 2015-12-16 2015-12-16
US201662331320P 2016-05-03 2016-05-03
US201662347486P 2016-06-08 2016-06-08
PCT/US2016/065228 WO2017105939A1 (en) 2015-12-16 2016-12-07 Modulators of complement activity

Publications (1)

Publication Number Publication Date
CY1123031T1 true CY1123031T1 (el) 2021-10-29

Family

ID=57758701

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100292T CY1123031T1 (el) 2015-12-16 2020-03-27 Ρυθμιστες της δραστικοτητας του συμπληρωματος

Country Status (25)

Country Link
US (2) US10835574B2 (el)
EP (3) EP4218790A1 (el)
JP (3) JP7126940B2 (el)
KR (1) KR20180094913A (el)
CN (2) CN108697759B (el)
AU (1) AU2016370210A1 (el)
BR (1) BR112018012174A2 (el)
CA (1) CA3007772A1 (el)
CY (1) CY1123031T1 (el)
DK (2) DK3685847T5 (el)
ES (2) ES2941640T3 (el)
FI (1) FI3685847T3 (el)
HR (2) HRP20230182T1 (el)
HU (1) HUE061759T2 (el)
IL (1) IL259762B (el)
LT (2) LT3389692T (el)
MX (2) MX2018007352A (el)
PL (2) PL3685847T3 (el)
PT (2) PT3389692T (el)
RS (2) RS60134B1 (el)
RU (2) RU2769701C2 (el)
SG (1) SG11201804721SA (el)
SI (2) SI3685847T1 (el)
TW (2) TWI779805B (el)
WO (1) WO2017105939A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3154561T3 (pl) 2014-06-12 2019-12-31 Ra Pharmaceuticals, Inc. Modulowanie aktywności dopełniacza
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
CA3007772A1 (en) 2015-12-16 2017-06-22 Ra Pharmaceuticals, Inc. Modulators of complement activity
CN110087668A (zh) 2016-12-07 2019-08-02 Ra制药公司 补体活性的调节剂
CA3084043A1 (en) 2017-12-04 2019-06-13 Ra Pharmaceuticals, Inc. Modulators of complement activity
TW202100179A (zh) 2019-03-08 2021-01-01 美商Ｒａ製藥公司 補體活性之調節劑
SG11202109837SA (en) * 2019-04-24 2021-10-28 Ra Pharmaceuticals Inc Compositions and methods for modulating complement activity
US20220257697A1 (en) 2019-06-04 2022-08-18 Ra Pharmaceuticals, Inc. Inflammatory disease treatment with complement inhibitors
BR112022002522A2 (pt) 2019-09-12 2022-08-16 Ra Pharmaceuticals Inc Tratamento de doenças neurológicas com inibidores do complemento
EP4142738A1 (en) 2020-04-30 2023-03-08 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
MX2024004750A (es) 2021-10-29 2024-05-13 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) contra el factor b del complemento (cfb) y sus metodos de uso.

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
AU684510B2 (en) 1993-05-28 1997-12-18 Chiron Corporation Method for selection of biologically active peptide sequences
WO1995001368A1 (en) 1993-06-29 1995-01-12 Ferring B.V. Improved synthesis of cyclic peptides
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998016636A1 (fr) 1996-10-17 1998-04-23 Mitsubishi Chemical Corporation Molecule permettant d'homologuer un genotype et un phenotype, et utilisation de celle-ci
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
AU738328B2 (en) 1997-01-21 2001-09-13 General Hospital Corporation, The Selection of proteins using RNA-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
TR200100366T2 (tr) 1998-08-07 2001-11-21 Emisphere Technologies, Inc. Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
CA2524534C (en) 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis
WO2005023866A2 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
JP4994039B2 (ja) 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2006066258A2 (en) 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
AU2006206848B2 (en) 2005-01-24 2012-05-31 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
ES2548700T3 (es) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
KR20170002684A (ko) 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
AU2007225044C1 (en) * 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP1876183A1 (en) 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
CA2666466C (en) 2006-10-10 2017-11-14 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
AU2008228247A1 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
CN101674824A (zh) 2007-04-30 2010-03-17 爱尔康研究有限公司 使用补体因子d抑制剂治疗老年性黄斑变性
KR20170023212A (ko) 2007-06-07 2017-03-02 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
RU2505311C2 (ru) * 2007-10-02 2014-01-27 Потентия Фармасьютикалз, Инк. Пролонгированная доставка аналогов компстатина из гелей
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
US20110190221A1 (en) 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
US20100093624A1 (en) 2008-07-30 2010-04-15 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
NZ614351A (en) 2008-11-10 2015-05-29 Alexion Pharma Inc Methods and compositions for treating complement-associated disorders
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
CN106390117A (zh) 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
EA201290286A1 (ru) 2009-11-05 2013-01-30 Алексион Кембридж Корпорейшн Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза
WO2011080102A2 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Glp-1 analogues and derivatives
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
EP2563359A1 (en) 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
MX2013011263A (es) * 2011-03-29 2014-03-27 Abbvie Inc Despliegue de cubierta mejorado en dispositivos de inyeccion automaticos.
AU2012239889B2 (en) 2011-04-08 2015-09-03 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
MX350445B (es) * 2011-05-05 2017-09-07 Wellstat Immunotherapeutics Llc Analogos del factor b del complemento y sus usos.
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (zh) 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
WO2013052736A2 (en) 2011-10-06 2013-04-11 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
CN104114574B (zh) 2012-02-20 2018-08-24 瑞典孤儿比奥维特鲁姆有限公司 结合人补体c5的多肽
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
ES2755104T3 (es) 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Inhibidores peptídicos y peptidomiméticos
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
EA201691481A1 (ru) 2014-03-20 2017-02-28 Инфларкс Гмбх ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
PL3154561T3 (pl) 2014-06-12 2019-12-31 Ra Pharmaceuticals, Inc. Modulowanie aktywności dopełniacza
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
ES2704299T3 (es) 2015-01-21 2019-03-15 Pacira Pharmaceuticals Inc Formulaciones de liposomas multivesiculares de ácido tranexámico
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
CA3007772A1 (en) 2015-12-16 2017-06-22 Ra Pharmaceuticals, Inc. Modulators of complement activity
CN110087668A (zh) 2016-12-07 2019-08-02 Ra制药公司 补体活性的调节剂
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
WO2019051436A1 (en) 2017-09-11 2019-03-14 Ra Pharmaceuticals, Inc. FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
CA3084043A1 (en) 2017-12-04 2019-06-13 Ra Pharmaceuticals, Inc. Modulators of complement activity
TW202100179A (zh) 2019-03-08 2021-01-01 美商Ｒａ製藥公司 補體活性之調節劑
SG11202109837SA (en) 2019-04-24 2021-10-28 Ra Pharmaceuticals Inc Compositions and methods for modulating complement activity

Also Published As

Publication number Publication date
US20180369322A1 (en) 2018-12-27
JP2022159479A (ja) 2022-10-17
TWI745320B (zh) 2021-11-11
ES2941640T3 (es) 2023-05-24
RU2769701C2 (ru) 2022-04-05
TWI779805B (zh) 2022-10-01
MX2018007352A (es) 2019-05-16
TW202200189A (zh) 2022-01-01
HRP20230182T1 (hr) 2023-04-14
DK3685847T3 (da) 2023-02-27
SG11201804721SA (en) 2018-07-30
AU2016370210A1 (en) 2018-06-21
US20210077572A1 (en) 2021-03-18
CN108697759A (zh) 2018-10-23
DK3685847T5 (da) 2024-08-26
IL259762B (en) 2020-06-30
IL259762A (en) 2018-07-31
EP3389692B1 (en) 2020-03-04
EP3685847A1 (en) 2020-07-29
JP7126940B2 (ja) 2022-08-29
EP3685847B1 (en) 2023-01-11
CN115920000A (zh) 2023-04-07
RU2020131790A3 (el) 2021-11-18
SI3389692T1 (sl) 2020-07-31
RU2018121615A3 (el) 2020-03-16
HRP20200508T1 (hr) 2020-09-04
JP2019504012A (ja) 2019-02-14
RU2020131790A (ru) 2020-10-20
LT3389692T (lt) 2020-04-27
TW201733609A (zh) 2017-10-01
JP7379615B2 (ja) 2023-11-14
RS64067B1 (sr) 2023-04-28
PT3685847T (pt) 2023-03-14
RS60134B1 (sr) 2020-05-29
EP4218790A1 (en) 2023-08-02
MX2022013454A (es) 2023-02-22
DK3389692T3 (da) 2020-03-30
RU2018121615A (ru) 2020-01-20
PL3685847T3 (pl) 2023-05-08
FI3685847T3 (fi) 2023-04-03
CN108697759B (zh) 2022-08-02
HUE061759T2 (hu) 2023-08-28
BR112018012174A2 (pt) 2018-12-04
LT3685847T (lt) 2023-03-27
SI3685847T1 (sl) 2023-05-31
EP3389692A1 (en) 2018-10-24
JP2024001300A (ja) 2024-01-09
CA3007772A1 (en) 2017-06-22
PT3389692T (pt) 2020-04-07
WO2017105939A1 (en) 2017-06-22
PL3389692T3 (pl) 2020-06-15
US10835574B2 (en) 2020-11-17
RU2733720C2 (ru) 2020-10-06
US11752190B2 (en) 2023-09-12
ES2781551T3 (es) 2020-09-03
EP4218790A8 (en) 2023-10-04
KR20180094913A (ko) 2018-08-24

Similar Documents

Publication Publication Date Title
CY1123031T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
CY1123853T1 (el) Ρυθμιστες nrf2
CY1122415T1 (el) Κυκλοπροπυλαμινες ως lsd1 αναστολεις
CY1122314T1 (el) Κυκλοπροπυλαμινες ως αναστολεις lsd1
CY1119531T1 (el) Ενωσεις και συνθεσεις για την ρυθμιση της δραστηριοτητας toy egfr
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
EA201691978A1 (ru) Соединения в качестве модуляторов ror гамма
EA201890204A1 (ru) Антибактериальные соединения
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201691582A1 (ru) Новые фармацевтические препараты
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201991997A1 (ru) Комбинированная терапия
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
BR112017010177A2 (pt) composição para tratamento de tecido
EA201791500A1 (ru) Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости